Description du projet
Une médecine personnalisée pour les patients atteints de cancer gastrique
Le cancer gastrique est la troisième cause principale de décès par cancer dans le monde. Le taux de survie des patients atteints de cancer gastrique avancé est d’environ 12 mois. Le projet LEGACy, financé par l’UE, améliorera les résultats du cancer gastrique en mettant en œuvre des mesures pour faciliter un diagnostic précoce et en suggérant des options thérapeutiques optimales en fonction des caractéristiques du patient. Le projet LEGACy aborde la médecine personnalisée sur trois niveaux de prévention en Europe centrale et orientale et en Amérique Centrale et du Sud. Pour ce faire, il analyse les causes du retard de diagnostic et procède également à une analyse intégrale des faits épidémiologiques corrélés au profil multiomique de ces patients. Enfin, le projet formera de jeunes chercheurs et sensibilisera le grand public sur les symptômes et les facteurs de risque du cancer gastrique.
Objectif
Globally, gastric cancer (GC) is the third leading cause of cancer death in both sexes worldwide (723,000 deaths, 8.8% of the total). The highest estimated mortality rates are in Eastern Asia (24 per 100,000 in men, 9.8 per 100,000 in women), the lowest in Northern America (2.8 and 1.5 respectively). High mortality rates are also present in both sexes in Central and Eastern Europe, and in Central and South America.
None strategies have improved prognosis in locally advanced stage III and IV GC. Therefore, an urgent intervention is needed. Epidemiological and molecular features of GCs can vary widely according to their histological type, location and genetic makeup of the tumour. The reasons behind these differences are multiple and complex and may include genetic susceptibility, strains of the bacterium Helicobacter pylori (H. pylori) and dietary factors. In particular, H. pylori infection plays a relevant role in GC incidence. Similarly, about 10% of GC patients are positive for the infection of the Epstein Barr Virus (EBV) . Most studies and current international databases on late-stage/advanced GC are largely based on Asian populations, in sharp contrast tumour biology and genome of EU and CELAC countries is poorly known.
From a public health standpoint, prevention can be conducted at three levels: primary, secondary, and for improving outcomes at the advanced stage of disease. In recent years, the arrival of personalized medicine has revolutionized available treatments for cancer patients.
The primary aim of LEGACY project is to improve GC outcomes by applying personalized medicine at the three levels of prevention: in EU and CELAC countries participating in this multicentre case-control study based on an “omics integrative epidemiology” conceptual model as a strategy to be extended worldwide.
Champ scientifique
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
46010 Valencia
Espagne